<VariationArchive RecordType="classified" VariationID="210940" VariationName="NM_001429.4(EP300):c.4836dup (p.Val1613fs)" VariationType="Duplication" Accession="VCV000210940" Version="6" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-04-09" DateCreated="2015-10-05" MostRecentSubmission="2015-10-05">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="208800" VariationID="210940">
      <GeneList>
        <Gene Symbol="EP300" FullName="E1A binding protein p300" GeneID="2033" HGNC_ID="HGNC:3373" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41092592" stop="41180077" display_start="41092592" display_stop="41180077" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41488613" stop="41576080" display_start="41488613" display_stop="41576080" Strand="+" />
          </Location>
          <OMIM>602700</OMIM>
          <Haploinsufficiency last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_001429.4(EP300):c.4836dup (p.Val1613fs)</Name>
      <CanonicalSPDI>NC_000022.11:41176301:TT:TTT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41176301" stop="41176302" display_start="41176301" display_stop="41176302" variantLength="1" positionVCF="41176301" referenceAlleleVCF="A" alternateAlleleVCF="AT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41572305" stop="41572306" display_start="41572305" display_stop="41572306" variantLength="1" positionVCF="41572305" referenceAlleleVCF="A" alternateAlleleVCF="AT" />
      </Location>
      <ProteinChange>V1587fs</ProteinChange>
      <ProteinChange>V1613fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.41572307dup" Assembly="GRCh37">
            <Expression>NC_000022.10:g.41572307dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.41176303dup" Assembly="GRCh38">
            <Expression>NC_000022.11:g.41176303dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009817.1" sequenceAccession="NG_009817" sequenceVersion="1" change="g.88694dup">
            <Expression>NG_009817.1:g.88694dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001362843.2" sequenceAccession="NM_001362843" sequenceVersion="2" change="c.4758dup">
            <Expression>NM_001362843.2:c.4758dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001349772.1" sequenceAccession="NP_001349772" sequenceVersion="1" change="p.Val1587fs">
            <Expression>NP_001349772.1:p.Val1587fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001429.4" sequenceAccession="NM_001429" sequenceVersion="4" change="c.4836dup" MANESelect="true">
            <Expression>NM_001429.4:c.4836dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001420.2" sequenceAccession="NP_001420" sequenceVersion="2" change="p.Val1613fs">
            <Expression>NP_001420.2:p.Val1613fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422" sequenceAccession="LRG_1422">
            <Expression>LRG_1422:g.88694dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422t1" sequenceAccession="LRG_1422t1">
            <Expression>LRG_1422t1:c.4836dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1422p1" sequenceAccession="LRG_1422p1" change="p.Val1613fs">
            <Expression>LRG_1422p1:p.Val1613fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA277265" DB="ClinGen" />
        <XRef Type="rs" ID="797045559" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001429.4(EP300):c.4836dup (p.Val1613fs) AND Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" Accession="RCV000194142" Version="6">
        <ClassifiedConditionList TraitSetID="6729">
          <ClassifiedCondition DB="MedGen" ID="C3150941">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2014-12-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2014-12-16" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2015-10-05" MostRecentSubmission="2015-10-05">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="6729" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15794" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ElementValue>
                <XRef ID="MONDO:0013364" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 2</ElementValue>
                <XRef ID="Rubinstein-Taybi+syndrome+2/9259" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">RSTS2</ElementValue>
                <XRef Type="MIM" ID="613684" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EP300</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353284" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C3150941" DB="MedGen" />
              <XRef ID="MONDO:0013364" DB="MONDO" />
              <XRef Type="MIM" ID="613684" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="458930" SubmissionDate="2015-09-15" DateLastUpdated="2015-10-05" DateCreated="2015-10-05">
        <ClinVarSubmissionID localKey="NM_001429.3(EP300):c.4836dup|Rubinstein-Taybi syndrome 2" />
        <ClinVarAccession Accession="SCV000247296" DateUpdated="2015-10-05" DateCreated="2015-10-05" Type="SCV" Version="1" SubmitterName="Genetic Services Laboratory, University of Chicago" OrgID="1238" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-12-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EP300" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001429.3:c.4836dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Rubinstein-Taybi syndrome 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="458930" TraitType="Disease" MappingType="Name" MappingValue="Rubinstein-Taybi syndrome 2" MappingRef="Preferred">
        <MedGen CUI="C3150941" Name="Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

